What are the treatment options for post‑acute sequelae of SARS‑CoV‑2 infection (long COVID)?

Treatment Options for Long COVID

There are currently no broadly effective treatments for long COVID, but symptom-specific and mechanism-targeted therapies show promise for subsets of patients, with the most critical principle being to avoid exercise in those with postexertional malaise, as it worsens symptoms in 75% of patients. 1

Symptom-Specific Pharmacological Approaches

The treatment strategy should be tailored to the dominant symptom cluster and underlying mechanism:

For Dysautonomia/POTS

• β-blockers (first-line pharmacological option)
• Pyridostigmine, fludrocortisone, or midodrine (alternatives based on symptom constellation)
• Non-pharmacological: Increase salt and fluid intake, IV saline, compression stockings 1

For Neuroinflammation and Pain

• Low-dose naltrexone shows promise across multiple symptoms including pain, fatigue, and neurological manifestations, with substantial anecdotal support from the patient community 1

For Mast Cell Activation/Histamine-Related Symptoms

• H1 and H2 antihistamines, particularly famotidine, following mast cell activation syndrome protocols
• These alleviate a wide range of symptoms but are not curative 1

For Immune Dysfunction

• Intravenous immunoglobulin (IVIG) for documented immune dysfunction
• Consider immunology consultation for implementation 1

For Abnormal Clotting/Microclots

• Anticoagulant regimens are particularly promising: one study showed complete symptom resolution in all 24 patients receiving triple anticoagulant therapy 1
• Apheresis shows promise but is expensive with uncertain long-term benefits 1

For Autoimmunity

• BC007 (investigational) neutralizes G protein-coupled receptor autoantibodies 1

Antiviral Approaches

Paxlovid (nirmatrelvir/ritonavir) deserves special attention:

• Case reports show resolution of long COVID symptoms with treatment 1
• When used during acute COVID-19, it reduced long COVID incidence by 25% 1
• May have both preventive and therapeutic potential, though more research is needed

Non-Pharmacological Management

Critical: Activity Pacing

• Pacing is essential for patients with postexertional malaise or ME/CFS-like symptoms
• Exercise is contraindicated and harmful—physical activity worsened 75% of patients and improved less than 1% 1
• Implement both physical and cognitive pacing strategies 1

Olfactory Dysfunction

• Olfactory training should be offered to all patients with smell loss due to its simplicity and safety 2
• Evidence is insufficient for pharmacological interventions (topical corticosteroids showed no benefit in one RCT) 2

Supplements with Potential Benefit

• Coenzyme Q10 and D-ribose for fatigue (based on ME/CFS literature) 1
• Pycnogenol showed statistically significant improvement in oxidative stress and quality of life scores 1

Emerging/Investigational Therapies

Recent scoping reviews identify additional promising options:

• Hyperbaric oxygen therapy 3
• Antifibrotic agents for pulmonary manifestations 3
• SSRIs for neuropsychiatric symptoms 3
• Sulodexide for endothelial dysfunction 1
• Probiotics for gastrointestinal and non-GI symptoms 1
• Stellate ganglion block for dysautonomia (case reports) 1

Critical Pitfalls to Avoid

1. Never prescribe graded exercise therapy or cognitive behavioral therapy as primary treatments—these are contraindicated and controversial even in ME/CFS 1, 2

2. Do not assume normal standard testing rules out long COVID—specialized testing (tilt table for POTS, microclot imaging, small fiber neuropathy assessment) may be needed 1

3. Recognize the heterogeneity—long COVID encompasses multiple distinct syndromes requiring different therapeutic approaches rather than a one-size-fits-all treatment 3

Clinical Algorithm

1. Identify dominant symptom cluster: dysautonomia, cognitive dysfunction, fatigue with postexertional malaise, pain, or clotting abnormalities
2. Screen for postexertional malaise: If present, implement pacing immediately and avoid exercise
3. Target specific mechanisms: Use symptom-specific pharmacotherapy as outlined above
4. Consider combination approaches: Many patients benefit from multiple simultaneous interventions
5. Monitor for autoimmunity and clotting abnormalities: These have specific targeted therapies
6. Discuss investigational options: Given limited approved treatments, clinical trial participation may be appropriate

The evidence base remains limited, with most recommendations drawn from ME/CFS literature and small pilot studies. The 2023 Nature Reviews Microbiology guideline provides the most comprehensive framework 1, while the 2022 ESCMID guidelines acknowledge insufficient evidence for most interventions 2.